title: Immunogenicity of Pertussis Booster Vaccination in Children and Adolescents with Inflammatory Bowel Disease: A Controlled Study.
abstract: There are limited data on antibody response to vaccination in patients with inflammatory bowel disease (IBD). In this study, we aimed to assess the immunogenicity of a booster dose of pertussis vaccine in pediatric patients with IBD and to compare their response with healthy controls.
  
  
  
  We performed a multicenter, prospective, and controlled trial. Eligible for inclusion were children and adolescents (11-18 year olds), with no history of pertussis booster immunization after the age of 6 years or history of pertussis. Study population was divided into 4 groups: patients with IBD receiving no immunosuppressive therapy (group 1), those on thiopurines only (group 2), those on thiopurines and TNF-α agents (group 3), and healthy controls (group 4). Patients and controls received 1 dose of pertussis vaccine intramuscularly and were asked to record adverse effects for 3 days after vaccination. The primary outcome measure was adequate vaccine response, defined as the concentration of anti-Bordetella pertussis antibodies >11 μg/mL, measured between 4 and 8 weeks after the vaccination.
  
  
  
  In total, 138 subjects (111 patients and 27 controls) were enrolled in the study. Rates of adequate vaccine response did not differ among the 4 study groups (P = 0.11). Moreover, those patients with IBD who were on immunosuppressive therapy did not differ from those who were not (90.6% versus 88.2%, P = 0.37). No serious adverse effects in relation to the administration of vaccine were noted.
  
  
  
  Booster dose of pertussis vaccine was immunogenic and safe in pediatric patients with IBD.
authors.affiliation: *Department of Pediatric Gastroenterology and Nutrition, Medical University of Warsaw, Warsaw, Poland;†Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland;‡Department of Pediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Wroclaw, Poland;§Department of Pediatrics, Medical University of Silesia, Katowice, Poland;‖Department of Pediatric Allergology, Gastroenterology and Nutrition, Medical University of Lodz, Lodz, Poland;¶Department of Health Promotion, Poznan University of Medical Sciences, Poznan, Poland;**Department of Pediatric Respiratory and Allergic Diseases, Medical University of Warsaw, Warsaw, Poland;††Department of Public Health, Faculty of Health Sciences, Medical University of Warsaw, Warsaw, Poland; and‡‡Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Warsaw, Poland.
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Banaszkiewicz
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Gawronska
authors.forename: Beata
authors.initials: B
authors.lastname: Klincewicz
authors.forename: Anna
authors.initials: A
authors.lastname: Kofla-Dłubacz
authors.forename: Urszula
authors.initials: U
authors.lastname: Grzybowska-Chlebowczyk
authors.forename: Ewa
authors.initials: E
authors.lastname: Toporowska-Kowalska
authors.forename: Ilona
authors.initials: I
authors.lastname: Malecka
authors.forename: Joanna
authors.initials: J
authors.lastname: Stryczynska-Kazubska
authors.forename: Wojciech
authors.initials: W
authors.lastname: Feleszko
authors.forename: Izabella
authors.initials: I
authors.lastname: Lazowska-Przeorek
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Karolewska-Bochenek
authors.forename: Jarosław
authors.initials: J
authors.lastname: Walkowiak
authors.forename: Janusz
authors.initials: J
authors.lastname: Slusarczyk
authors.forename: Andrzej
authors.initials: A
authors.lastname: Radzikowski
authors.forename: Urszula
authors.initials: U
authors.lastname: Demkow
authors.forename: Piotr
authors.initials: P
authors.lastname: Albrecht
mesh_terms: D000293:Adolescent; D000917:Antibody Formation / Q000276:immunology*; D016022:Case-Control Studies; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007117:Immunization, Secondary / Q000379:methods*; D015212:Inflammatory Bowel Diseases / Q000276:immunology / Q000628:therapy*; D008297:Male; D010567:Pertussis Vaccine / Q000627:therapeutic use*; D011379:Prognosis; D011446:Prospective Studies; D014611:Vaccination
chemical_list: D010567:Pertussis Vaccine